Fulvestrant Versus Capecitabine as Maintenance Therapy After First-line Chemotherapy in Patients With HR+/HER2- Metastatic Breast Cancer

NCT04263298 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

210

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Breast Cancer

Interventions

DRUG: Fulvestrant
DRUG: Capecitabine Oral Product

Sponsor

Herui Yao